Aug 2026· Breast Cancer· Vol 33, pp. 1214 - 1226· 0 citations· 24 references
Medicine
TL;DR
Landmark-based conditional survival analysis provides clinically meaningful, time-updated prognostic information in HR+/HER2- mBC treated with first-line CDK4/6 inhibitors and support the integration of milestone-based conditional survival estimates alongside conventional baseline survival metrics in the CDK4/6i era.
In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.
Vali Aliyev, Z. Birsin, M. Günaltılı et al.· Cerrahpasa Medical Journal· 0 citations
Real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis, and first-line use showed a trend toward longer PFS, while later-line use showed a numerical trend toward longer OS.
S. Yıldırım, Büşra Bülbül, Bekir Ucun et al.· Cancers· 0 citations
Findings support an individualized, risk-adapted sequencing approach in carefully selected patients but do not establish equivalence or justify routine deferral.
Pınar Kubilay Tolunay, Bediz Kurt İnci, B. Karabuğa et al.· Biomedicines· 0 citations
BACKGROUND AND OBJECTIVES
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, yet the cost architecture across the full treatment trajectory remains poorly characterized....
Munenobu Kashiwa, Kensuke Moriwaki· Clinical drug investigation· 0 citations
Hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer is the most common biologic subtype and carries a persistent risk of recurrence, particularly in patients with high‐risk, early‐stage disease. Cyclin‐dependent kinase 4 and 6 inhibitors, initially established as a standard compon...
Austin D. Williams, Anna Weiss· Cancer· 0 citations
It was unable to demonstrate an association between HER2 status and PFS or OS among patients receiving CDK4/6 inhibitor therapy, and the clinical significance of HER2 status in patients treated with CDK4/6 inhibitors remains unclear.
Esra Aydın, Ç. Öztürk, Oğuzhan Okçu et al.· Medical Journal of Western B...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.